Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Record of Telephone Conversation - September 19, 2009 - Prevnar 13

System Info - 120967  SMITH, MICHAEL J  23-Feb-2010 16:27:07  SMITHM


Submission Type: Original Application   Submission ID:  125324/0    Office: OVRR  

Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein)

Wyeth Pharmaceuticals Inc.          

Telecon Date/Time:  19-SEP-2009 01:04 PM     Initiated by FDA?  Yes
Telephone Number:    

Communication Categorie(s):


Telecon Summary:
E-mail: Procedures regarding generating working cell banks

FDA Participants:   Julie Vaillancourt and Mike Smith

Non-FDA Participants:    Jack Love, Carmel Devlin and Elizabeth Edwards

Trans-BLA Group: No

Related STNs:  None

Related PMCs:  None

Telecon Body:
From: Love Jack []
Sent: Saturday, September 19, 2009 1:04 PM
To: Vaillancourt, Julienne; Smith, Michael (CBER)
Cc: Devlin Carmel; Edwards Elizabeth
Subject: Follow-up on telephone call from Tina Rocklein and Willie Vann

Julie and Mike,
On Thursday, Tina and Willie called me and requested some additional information.  One purpose of this email is to let Tina know where the documents are that she could not find in the dossier.  Wyeth has provided the procedures for each of the 13 serotypes and CRM197 under 3.2.S.2.3 Procedure for Working Cell Bank Generation.  Additionally, the tests and specifications to be used for the new working cell banks are listed in 3.2.S.2.3 Cell Banking System, Generation and Testing.  Copies of these documents for serotype 1 are attached, and there are similar ones for every other serotype and CRM197.  In addition, I will be submitting an amendment to the BLA for approval to file the change to new Working Cell Banks via the Annual Report, as Tina requested.  Will you please forward this email to Tina?

Additionally, I am putting together some information on the rationale for linking specifications for ---------------(b)(4)------------------ to clinical data.  I have not yet had an opportunity to review the specs for -------(b)(4)----- but we will look into this as well.  In addition, I will be forwarding to the BLA as Willie requested the tables showing the specifications that Wyeth has tightened recently.  These will be submitted to Module 1 on the BLA.  As you and I discussed about 2 weeks ago, Wyeth commits to releasing all commercial lots according to the tighter specifications and post-approval to filing the supporting documents for these specification changes.  The reason for submitting the additional documents post-approval is that there are numerous documents that will have to be updated, such as Justification for Specifications, Post-approval Stability protocols, Batch Analyses, and the Module 2 Introduction and Module 2 summaries, and most of these have 13 versions.  We had discussed at the meeting on September 1st that there were no additional CMC requirements pre-approval, so this seems like a reasonable compromise, please let me know that this approach is acceptable.


Jack D. Love, Ph.D.
Assistant Vice President
Vaccine Regulatory Affairs
Wyeth Pharmaceuticals, Inc.
One Blue Hill Plaza BH 21125
Pearl River, NY 10965

Contact FDA

(800) 835-4709
(240) 402-8010
Consumer Affairs Branch (CBER)

Division of Communication and Consumer Affairs

Office of Communication, Outreach and Development

Food and Drug Administration

10903 New Hampshire Avenue

Building 71 Room 3103

Silver Spring, MD 20993-0002

Page Last Updated: 03/26/2010
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English